Study to Create Potential Cell-Based Therapies to Treat Human Disease and Disability
This is a research study in which your cells will be used for somatic cell nuclear transfer (SCNT), and/or genetic reprogramming research which may result in the production of stem cell lines. This study does not provide treatment.
Procedure: Improving the scientific process of human cell reprogramming
|Study Design:||Time Perspective: Prospective|
|Official Title:||Derivation of Primary Donor Cell Lines for Human Cell Reprogramming|
|Study Start Date:||September 2007|
|Estimated Primary Completion Date:||January 2010 (Final data collection date for primary outcome measure)|
It is thought that studies of genetic reprogramming and SCNT using human cells have the potential to give us new basic knowledge about human development. Current work will focus on developing this basic knowledge. In the future, human embryonic stem cell lines (hESC) derived from genetic reprogramming and SCNT may also have the potential to develop into cell types that are useful for cell-based therapies to treat human disease and disability.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00628199
|United States, California|
|Stanford University School of Medicine|
|Stanford, California, United States, 94305|
|Principal Investigator:||Renee A. Reijo Pera||Stanford University|